Differences among conventional, atypical and novel putative D2/5-HT1A antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys

Behavioural Brain Research

Volumn 203, Issue 2, 2009, Pages 288-295

  Auclair, Agnès L ^a   Kleven, Mark S ^b   Barret Grévoz, Catherine ^a   Barreto, Martine ^a   Newman Tancredi, Adrian ^a   Depoortère, Ronan ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b Scientific Operations   (United States)

Author keywords

5 HT1A receptor; Antipsychotic; Catalepsy associated behaviour; Extra pyramidal symptoms; Monkey

Indexed keywords

5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CLOZAPINE; EMONAPRIDE; F 15063; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; CATALEPSY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; EXTRAPYRAMIDAL SYNDROME; FEMALE; MONKEY; NONHUMAN; PRIORITY JOURNAL;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BENZODIAZEPINES; BENZOXAZOLES; CATALEPSY; CLOZAPINE; DIBENZOTHIAZEPINES; DIOXANES; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; MACACA FASCICULARIS; PIPERAZINES; QUINOLONES; REMOXIPRIDE; RISPERIDONE; SEROTONIN AGONISTS; THIAZOLES; TROPANES; VIDEO RECORDING;

EID: 67649656102     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.05.015     Document Type: Article

References (79)

1. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
2. Assie M.B., Bardin L., Auclair A., Consul-Denjean N., Sautel F., Depoortere R., et al. F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice. Naunyn Schmiedebergs Arch Pharmacol 375 (2007) 241-250
3. Baldessarini R.J., and Frankenburg F.R. Clozapine. A novel antipsychotic agent. N Engl J Med 324 (1991) 746-754
4. Bardin L., Auclair A., Kleven M.S., Prinssen E.P., Koek W., Newman-Tancredi A., et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol 18 (2007) 103-118
5. Bardin L., Kleven M.S., Barret-Grevoz C., Depoortere R., and Newman-Tancredi A. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31 (2006) 1869-1879
6. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., and Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 124 (1996) 159-167
7. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., and Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14 (1996) 111-123
8. Boulay D., Depoortere R., Louis C., Perrault G., Griebel G., and Soubrie P. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46 (2004) 1121-1129
9. Brahm N.C., McElwain D.L., and Brown R.C. Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. Am J Health Syst Pharm 64 (2007) 827-829
10. Broekkamp C.L., Oosterloo S.K., Berendsen H.H., and van Delft A.M. Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine. Naunyn Schmiedebergs Arch Pharmacol 338 (1988) 191-195
11. Casey D.E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 99 (1989) S47-S53
12. Casey D.E. Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol Bull 27 (1991) 47-50
13. Casey D.E. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4 (1991) 109-120
14. Casey D.E. Serotonergic dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology (Berl) 112 (1993) S55-S59
15. Casey D.E. Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Psychopharmacology (Berl) 124 (1996) 134-140
16. Castner S.A., Goldman-Rakic P.S., and Williams G.V. Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia. Psychopharmacology (Berl) 174 (2004) 111-125
17. Chou Y.H., Halldin C., and Farde L. Occupancy of 5-HT1A receptors by clozapine in the primate bran: a PET study. Psychopharmacology (Berl) 166 (2003) 234-240
18. Christoffersen C.L., and Meltzer L.T. Reversal of haloperidol-induced extrapyramidal side effects in Cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology 18 (1998) 399-402
19. Claustre Y., Peretti D.D., Brun P., Gueudet C., Allouard N., Alonso R., et al. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 28 (2003) 2064-2076
20. Coffin V.L., Latranyi M.B., and Chipkin R.E. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors. J Pharmacol Exp Ther 249 (1989) 769-774
21. Crowley T.J., Stynes A.J., Hydinger M., and Kaufman I.C. Ethanol, methamphetamine, pentobarbital, morphine, and monkey social behavior. Arch Gen Psychiatry 31 (1974) 829-838
22. Depoortere R., Auclair A.L., Bardin L., Bruins S.L., Kleven M.S., Colpaert F., et al. F15063, a compound with D2/D3 antagonist 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. Br J Pharmacol 151 (2007) 266-277
23. Depoortere R., Bardin L., Auclair A.L., Kleven M.S., Prinssen E., Colpaert F., et al. F15063, a compound with D2/D3 antagonist 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia. Br J Pharmacol 151 (2007) 253-265
24. Depoortere R., Boulay D., Perrault G., Bergis O., Decobert M., Francon D., et al. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28 (2003) 1889-1902
25. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., and Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49 (1992) 538-544
26. Feenstra R.W., de Moes J., Hofma J.J., Kling H., Kuipers W., Long S.K., et al. New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. Bioorg Med Chem Lett 11 (2001) 2345-2349
27. Feenstra R.W., Long S.K., Kuipers W., van der Heyden J.A., Tulp M.T., and Kruse C.G. New approaches for psychosis treatment: design, synthesis and SAR of ligands binding to dopamine D2 and serotonin 5-HT1A. Drugs Future 27 (2002)
28. Fenton H.M., Hall N.R., Gerhardt S., Noreika L., Neale R., and Liebman J.M. Avoidance and ICSS behavioral models dissociate TL-99 and 3-PPP from dopamine receptor antagonists. Eur J Pharmacol 91 (1983) 421-430
29. Garver D.L., Schlemmer Jr. R.F., Maas J.W., and Davis J.M. A schizophreniform behavioral psychosis mediated by dopamine. Am J Psychiatry 132 (1975) 33-38
30. Gerlach J., and Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol 10 (1995) 39-48
31. Goff D.C., Midha K.K., Brotman A.W., McCormick S., Waites M., and Amico E.T. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11 (1991) 193-197
32. Goff D.C., Posever T., Herz L., Simmons J., Kletti N., Lapierre K., et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18 (1998) 296-304
33. Gyertyan. RGH-188, a D3/D2 dopamine receptor antagonist/partial agonist antipsychotic candidate: behavioural profile, congress program and abstract book. Dopamine 50 years. Göteborg, Sweden; 2007.
34. Invernizzi R.W., Cervo L., and Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27 (1988) 515-518
35. Jentsch J.D., Elsworth J.D., Taylor J.R., Redmond Jr. D.E., and Roth R.H. Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the nonhuman primate: implications for schizophrenia. Adv Pharmacol 42 (1998) 810-814
36. Jentsch J.D., Roth R.H., and Taylor J.R. Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity. Biol Psychiatry 48 (2000) 415-424
37. Jentsch J.D., Taylor J.R., Elsworth J.D., Redmond Jr. D.E., and Roth R.H. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience 90 (1999) 823-832
38. Kapur S., Remington G., Zipursky R.B., Wilson A.A., and Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57 (1995) L103-L107
39. Kleven M.S., Assie M.B., Cosi C., Barret-Grevoz C., and Newman-Tancredi A. Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation. Psychopharmacology (Berl) 177 (2005) 373-380
40. Kleven M.S., Barret-Grevoz C., Bruins S.L., and Newman-Tancredi A. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49 (2005) 135-143
41. Kleven M.S., and Koek W. Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J Pharmacol Exp Ther 279 (1996) 1211-1219
42. Kumar R., Palit G., and Dhawan B.N. Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur J Pharmacol 462 (2003) 133-138
43. Liebman J., and Neale R. Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects. Psychopharmacology (Berl) 68 (1980) 25-29
44. Liebman J.M., Gerhardt S.C., and Gerber R. Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology (Berl) 97 (1989) 456-461
45. Linn G.S., O'keeffe R.T., Lifshitz K., Schroeder C., and Javitt D.C. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology (Berl) 192 (2007) 27-38
46. Marinkovic D., Timotijevic I., Babinski T., Totic S., and Paunovic V.R. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 18 (1994) 537-544
47. Mattay VS, Casey DE: Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia, in Schizophrenia. Edited by Hirsch SR, Weinberger DR. Blackwell Scientific Science, 2003, pp 552-72.
48. McCreary A.C., Glennon J.C., Ashby Jr. C.R., Meltzer H.Y., Li Z., Reinders J.H., et al. SLV313 (1-(2,3-dihydro-benzo[14]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 32 (2007) 78-94
49. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21 (1999) S106-S115
50. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1159-1172
51. Migler B.M., Warawa E.J., and Malick J.B. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology (Berl) 112 (1993) 299-307
52. Moss L.E., Neppe V.M., and Drevets W.C. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 13 (1993) 204-209
53. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., and Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25 (2001) 476-488
54. Neal-Beliveau B.S., Joyce J.N., and Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265 (1993) 207-217
55. Newman-Tancredi A., Assie M.B., Martel J.C., Cosi C., Slot L.B., Palmier C., et al. F15063, a potential antipsychotic with D(2)/D(3) antagonist 5-HT(1A) agonist and D(4) partial agonist properties: (I) in vitro receptor affinity and efficacy profile. Br J Pharmacol 151 (2007) 237-252
56. Owens D.G. Adverse effects of antipsychotic agents. Do newer agents offer advantages?. Drugs 51 (1996) 895-930
57. Peacock L., and Gerlach J. New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. Psychopharmacology (Berl) 144 (1999) 189-197
58. Porsolt R.D., and Jalfre M. Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology (Berl) 75 (1981) 16-21
59. Prinssen E.P., Colpaert F.C., and Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453 (2002) 217-221
60. Prinssen E.P., Kleven M.S., and Koek W. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl) 144 (1999) 20-29
61. Prinssen E.P., Koek W., Colpaert F.C., and Kleven M.S. Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. Behav Pharmacol 11 (2000) 299-305
62. Prinssen E.P., Koek W., and Kleven M.S. Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: a role for tonic activation of 5-HT(1A) receptors. Eur J Pharmacol 395 (2000) 143-147
63. Rosenzweig-Lipson S., and Bergman J. Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynaphthoxazine by dopamine antagonists in monkeys. J Pharmacol Exp Ther 265 (1993) 1039-1046
64. Rosenzweig-Lipson S., and Bergman J. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys. Eur J Pharmacol 260 (1994) 237-241
65. Rush D.K. Shuttlebox. Sidman avoidance in rhesus monkeys: day of week and amphetamine effects. Pharmacol Biochem Behav 25 (1986) 145-148
66. Schlemmer R.F., Casper R.C., Siemsen F.K., Garver D.L., and Davis J.M. Behavioral changes in a juvenile primate social colony with chronic administration of d-amphetamine. Psychopharmacol Commun 2 (1976) 49-59
67. Schlemmer R.F., and Davis J.M. A comparison of three psychotomimetic-induced models of psychosis in nonhuman primate social colonies. Prog Clin Biol Res 131 (1983) 33-78
68. Schlemmer R.F., Jackson J.A., Preston K.L., Bederka Jr. J.P., Garver D.L., and Davis J.M. Phencyclidine-induced stereotyped behavior in monkeys: antagonism by pimozide. Eur J Pharmacol 52 (1978) 379-384
69. Swainston H.T., and Perry C.M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64 (2004) 1715-1736
70. Tauscher J., Jones C., Remington G., Zipursky R.B., and Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7 (2002) 317-321
71. Tauscher J., Kufferle B., Asenbaum S., Tauscher-Wisniewski S., and Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 162 (2002) 42-49
72. Tollefson G.D., Beasley Jr. C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154 (1997) 457-465
73. Wadenberg M.L., and Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm Gen Sect 83 (1991) 43-53
74. Wadenberg M.L., Cortizo L., and Ahlenius S. Evidence for specific interactions between 5-HT1A and dopamine D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat. Pharmacol Biochem Behav 47 (1994) 509-513
75. Wadenberg M.L., Soliman A., VanderSpek S.C., and Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 25 (2001) 633-641
76. Wadworth A.N., Heel R.C., and Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 40 (1990) 863-879
77. Wolf W. DU-127090 Solvay/H Lundbeck. Curr Opin Invest Drugs 4 (2003) 72-76
78. Yang S.Y., Kao Yang Y.H., Chong M.Y., Yang Y.H., Chang W.H., and Lai C.S. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 81 (2007) 586-594
79. Gerlach J., and Casey D.E. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 14 (1990) 103-112